Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation

Basic Information

Funding Cycle : 2022-2023
Name : Smith Giri
Type of Award : Career Development Award
Home Institution : University of Alabama Birmingham
Host Institution : University of North Carolina at Chapel Hill


This research project focuses on optimizing melphalan dosing for older adults undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM). While ASCT with high-dose melphalan is effective, older adults are at increased risk of severe toxicities, impacting their quality of life. Currently, there’s uncertainty about the appropriate melphalan dose for older adults, with many opting for reduced doses due to concerns about toxicity. However, this approach lacks sufficient evidence and leads to wide variability in melphalan exposure, which can result in unnecessary toxicities. The study aims to address this by developing strategies to individualize melphalan dosing, aiming to minimize toxicity while maintaining treatment efficacy. This research seeks to provide much-needed guidance for optimizing ASCT in older adults with MM, ultimately improving patient outcomes and quality of life.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events